Advertisement

 

 

Seroprevalence of Human Herpesvirus 8 and its Impact on the Hemoglobin Level in Patients of End Stage of Renal Diseases.

Seroprevalence of Human Herpesvirus 8 and its Impact on the Hemoglobin Level in Patients of End Stage of Renal Diseases.
Author Information (click to view)

Fang Q, Wang X, Liu Z, Zhu M, Ding M, Minhas V, Wood C, Zhang T,


Fang Q, Wang X, Liu Z, Zhu M, Ding M, Minhas V, Wood C, Zhang T, (click to view)

Fang Q, Wang X, Liu Z, Zhu M, Ding M, Minhas V, Wood C, Zhang T,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of medical virology 2017 09 06() doi 10.1002/jmv.24937

Abstract

The incidence of Kaposi’s sarcoma (KS) is increasing among renal transplant recipients. Patients with end-stage renal disease (ESRD) are immunocompromised and are candidates for renal transplantation, but HHV8 seroprevalence in ESRD patients has not been well documented. A cross-sectional study of 286 ESRD patients and 281 matched subjects without kidney disease was conducted at the First People’s Hospital of Huzhou, Zhejiang province to explore the epidemiologic features of HHV8 among ESRD patients in China. Blood samples were collected and HHV8 antibodies and serologic indices were measured. The seroprevalence of HHV8 was 15.3% for ESRD patients and 8.9% for the comparison group. A significant difference in the geometric mean titer (GMT) of the HHV8 antibodies was detected between ESRD patients and the comparison group (617.1 vs. 291.7; P = 0.042). The average level of hemoglobin was 11.56 ± 1.78 g/dl for the ESRD group and 13.73 ± 1.42 g/dl for the comparison group, (P > 0.05). Multiple linear regression revealed a negative association between HHV8 infection and plasma hemoglobin concentration (β = -0.682, P = 0.036). We found a higher HHV8 prevalence and a higher level of HHV8 antibody GMT in ESRD patients than the comparison group, which indicate a high risk of post-transplantation KS. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

7 − 5 =

[ HIDE/SHOW ]